Key Drivers
- High Margins
- Strong Cash Flow
- Margin Compression
AIAI Summary
REGN remains a financially elite biotech, but the investment case has shifted from “beat-and-raise” to proving it can sustain growth beyond Dupixent and offset legacy Eylea decline amid rising pricing pressure—until the stock reclaims the 720–725 resistance zone with follow-through, it stays a hold, not a clear buy.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High Margins
- •Strong Cash Flow
- •Margin Compression
REGN stands out for strong profitability, solid cash generation, and a conservative balance sheet, but recent margin pressure and a non-cheap valuation suggest the stock is more of a quality hold than a bargain.
Price Behavior
Key Price Behavior Insights:
- •Support holding
- •Weak rebound
- •Mid-700s ceiling
REGN remains in a fragile downtrend, with $686 support holding and $720-$725 resistance capping a weak rebound that has failed to regain the mid-$700s
Brief rebound from $686.36 to $723.41 quickly faded back to $698.25
Sentiment & News
Key News Insights:
- •Strong Q1 beat
- •Buyback support
- •Eylea pressure
Regeneron delivered a strong Q1 earnings and revenue beat with a $3B buyback and Dupixent/Eylea HD strength, but the stock lagged as investors focused on legacy Eylea pressure, pricing concessions, and competitive risks.
The news is mildly positive for long-term fundamentals, but near-term upside may remain limited by product-mix and pricing concerns
Similar Companies in Healthcare
Other companies in the same sector with AI ratings